Background: The long-term outcome of antidepressant-refractory depression is not well known. Therefore, the present study investigated the long-term outcome of 26 antidepressant-refractory patients with depression, whom we had studied and treated in
Introduction
Antidepressants are clearly beneficial in the treatment of major depression.
However, response rates to a variety of antidepressants (classified by more than 50% reduction in depression rating scales) are generally 60-70% (Thase and Rush, 1995; Janicak et al., 2002) . However, the remaining 30-40% of patients do not sufficiently improve, even if they take the adequate or maximum doses of antidepressants for a sufficient period of time (i.e., a minimum of the equivalent of 150 mg of imipramine for 4 weeks). Half of depressed patients who are non-responders to their first antidepressant may respond following a change to a second antidepressant (typically a drug with a different pharmacological profile) or a pharmacologically reasonable combination therapy consisting of two antidepressants (Thase and Rush, 1995; Lam et al., 2002) . Despite multiple pharmacological interventions, 5-10% of patients remain depressed (Inoue et al., 2002) . Depressed patients, who are treatment-resistant (or refractory) to multiple, adequate antidepressant treatments, have been widely observed and extensively studied during the last two decades (Thase and Rush, 1995; Stimpson et al., 2002) .
As indicated by Roose (1990) , the most important issue in treatment-resistant depression is its definition. The term "(antidepressant) treatment-resistant depression" should be applied to patients who do not respond to an antidepressant given in adequate amount for a sufficient duration (Roose, 1990; Halpern and Glassman, 1990) , and should be distinguished from intolerant patients, who are unable to tolerate an adequate dose of an antidepressant due to adverse effects, and non-compliant patients; these latter two cases are referred to as pseudorefracotry depression (Möller, 1992) . Thase and Rush (1995) defined "(antidepressant) treatment-refractory depression" as treatment nonresponse (i.e., persistence of significant depressive symptoms) despite at least two treatment trials with drugs from different pharmacological classes, each used in an adequate dose for a sufficient period of time (Thase and Rush, 1995) . This definition is reasonable because clinical findings suggest that 20-70% of nonresponders will respond to a different type of antidepressant (Thase and Rush, 1995) . However, most studies on antidepressant-resistant depression or antidepressant-refractory depression have investigated depressed patients who had not responded to only one adequate antidepressant treatment (for a review see Thase and Rush, 1995; Stimpson et al., 2002) .
The primary reason why these studies have not investigated patients who have not responded to two or more antidepressants with different pharmacological properties is the difficulty of obtaining a large sample size as a result of this stricter definition of antidepressant-refractory depression.
The effects of augmentation therapies utilizing lithium or thyroid hormones have been studied in open trials and randomized controlled trials. The results of these studies have shown that these augmentation therapies are effective in the treatment of refractory depression during the relatively short period of the clinical trials (Thase and Rush, 1995; Stimpson et al., 2002) . However, there has been no study of the long-term use of augmentation therapies for depression in naturalistic settings.
The long-term outcome and prognosis of antidepressant-refractory depression is not well known, although several clinical studies have investigated the treatment and symptomatology of antidepressant-refractory depression (Roose et al., 1986; Thase and Rush, 1995) . We reported the demographic characteristics and symptoms of antidepressant-refractory depression and the efficacy of augmentation therapies (Inoue et al., 1996a) . In 1995, 34 depressed patients (9 bipolar, 25 unipolar) were studied, and a follow-up study of these patients with antidepressant-refractory depression was conducted. In the present study, outcome for antidepressant-refractory depression is reported by a prospective long-term follow-up study. To assess full remission and improvement of depression, we used the Global Assessment of Functioning (GAF) Scale (DSM-III-R) rather than the Hamilton Depression Rating Scale (HDRS).
Methods

Study design
The present research was a naturalistic follow-up study of antidepressant-refractory depression, including both bipolar and unipolar depressed patients. In 1995, we investigated the demographic characteristics, symptoms, and treatment responses to augmentation therapies of 34 antidepressant-refractory depressed patients (9 bipolar, 25 unipolar) (Inoue et al., 1996a) . Each patient had satisfied the DSM-III-R criteria for major depression with melancholia or bipolar disorder, depressed in the current depression episode. Inclusion criteria required moderate depressed symptoms after adequate treatment with two or more antidepressants (i.e., a minimum of the equivalent of 150 mg of imipramine for 4 weeks). In 1995, tricyclic and tetracyclic antidepressants were available in Japan; however, monoamine oxidase inhibitors, serotonin-noradrenaline reuptake inhibitors, and selective serotonin reuptake inhibitors had not yet been approved.
According to the Clinical Global Impressions (CGI) scale (National Institute of Mental Health, 1985) , treatment efficacies were evaluated as worse, no change, minimally improved, much improved, or very much improved. Patients rated very much improved or much improved were regarded as the responders. Following the completion of this study, these patients continued to attend our department and receive treatment.
Treatment, symptoms, and social functioning were prospectively recorded for 7 years, from 1995 until 2002.
Patients
Of the subjects in our 1995 study, patients who were followed up for one or more years were enrolled in the present study. Depressed patients with brain MRI or EEG evidence of organic brain disease were excluded from the present study. Patients with concurrent significant medical problems were also excluded from the research. From the 34 patients in the 1995 study, a total of 26 patients (5 bipolar and 21 unipolar, according to the 1995 diagnoses) were investigated.
Assessment
The authors investigated the current diagnosis, severity of symptoms, medication, social functioning (employment, etc), GAF scores, whether the patients had experienced full remission for 7 years, and whether the patients had discontinued medication due to full remission. Treatment efficacies of various augmentation therapies have been evaluated according to the CGI scale (National Institute of Mental Health, 1985) .
Clinical pharmacological studies often use a score of 7 or less on the 17-items HDRS (Thase and Rush, 1995) as a definition of remission; however, symptomatic improvement does not fully account for the functional recovery observed in fully remitted patients (Lenderking et al., 1999; Lecrubier, 2002) . Although DSM-III-R defines full remission as "no significant signs or symptoms of the disturbance during the past 2 months", the achievement of an asymptomatic state with a full, functional recovery (i.e., a complete recovery) has traditionally been viewed as full remission in depression and is a fundamental goal for the treatment of depression (Kraepelin, 1913; Weitbrecht, 1973; Lecrubier, 2002) . Therefore, a score of 80 or higher on the GAF scale is a good and straightforward indicator of full remission.
Results
Diagnosis
After the mean follow-up period of 5.7 years, among the 15 patients with major depression, single episode, 1 patient was diagnosed with major depression, recurrent, 4 patients were diagnosed with bipolar disorder, while the diagnosis of the remaining 10 patients remained major depression, single episode (Tables 1A and 1B) . Of 6 patients diagnosed in 1995 with major depression, recurrent, 1 patient was diagnosed with bipolar disorder, and 5 patients were diagnosed with major depression, recurrent. The 1995 diagnoses of 5 bipolar patients were not changed (Table 1A) . Of the 21 unipolar depressed patients, 5 diagnoses were changed to bipolar disorder.
In 2002, the 26 subjects consisted of 10 bipolar patients, 6 patients with major depression, recurrent, and 10 patients with major depression, single episode.
Outcome
During the long-term follow-up period, we confirmed that 8 of 10 patients diagnosed with bipolar depression and 9 of 16 patients diagnosed with unipolar depression achieved full remission (Table 2A) . Recurrence occurred in only 2 of 9 patients diagnosed with remitted unipolar depression, and 1 patient with recurrence remitted again; however, 1 patient had moderate depression at the final observation after two recurrences and one remission (Table 2B) After the follow-up period, thirteen patients (5 bipolar, 8 unipolar) still had depression: 2 severe, 2 moderate, and 9 mild (Tables 1A and 1B ). In 7 of 13 patients, depression has continued since diagnosis in 1995 despite adequate antidepressant treatment and various augmentation therapies: one moved to a different hospital because of home relocation in year 1, however, the other 6 patients now receive treatment as outpatients at our department.
Treatment
The 26 patients in this study received two or more antidepressants and various augmentation therapies. Four patients were treated with ECT, but the efficacy was transient and all patients relapsed (data not shown). Augmentation therapies contributory to full remission were noted and shown in Tables 2A and 2B. In 9 of 13 patients with full remission at the final evaluation, the addition of dopamine receptor agonists (bromocriptine or pergolide) to adequate doses of conventional antidepressants was effective. The combination of lithium and dopamine receptor agonists with antidepressants was effective in 1 patient. The combination of lithium and L-thyroxine with antidepressants was effective in 2 patients.
All patients received lithium augmentation trials, and 4 (1 bipolar, 3 unipolar according to 1995 diagnosis) of 26 patients (15%) were lithium responders. As the diagnoses were changed after the long-term follow-up, these four patients were 3 bipolar and 1 unipolar patients at the final evaluation.
Long-term use of various augmentation therapies, such as lithium, thyroid hormone and dopamine receptor agonists, did not cause any serious side effects or any sequelae.
No cases of rapid cycling were observed during the follow-up period. Among the patients in this study, the long-term use of antidepressants clearly did not cause mixed or (hypo)manic episodes.
Discussion
In the present study, subsequent to long-term follow-up (mean, 5.7 years, range, 1-7 years), the diagnoses of 5 (24%) of 21 patients with unipolar antidepressant-refractory depression were changed to bipolar disorder. There has been no research conducted on the conversion from unipolar depression to bipolar disorder in antidepressant-refractory depression. However, in non-refractory depression, a similar finding that 70 (12.5%) of 599 unipolar depressed patients were converted to bipolar disorder in a prospective observation period of up to 11 years was reported by Akiskal et al. (1995) . In 1995, our patients had been depressed for an average of 5 years, indicating that these unipolar depressed patients were observed for an average of 11 years, a period similar to the study by Akiskal et al. (1995) . In comparison to non-refractory depression, there may be more converters from unipolar to bipolar in antidepressant-refractory depression.
Recommendation of more intensive use of mood stabilizers might be considered after the completion of future research. Furthermore, the increased tendency for patients diagnosed with unipolar antidepressant-refractory depression to become manic in comparison to non-refractory unipolar depression should be noted. In the end, 10 (38%) of 26 treatment-refractory depressed patients were diagnosed as bipolar at the final evaluation. This relatively high prevalence of bipolar disorder is comparable to the 46% prevalence of bipolar I and II disorders in patients with antidepressant-resistant depression recently observed by Sharma et al. (2005) . As antidepressant-refractory depression includes more bipolarity, this suggests that bipolarity plays an important role in the pathophysiology of a subgroup of patients with antidepressant-refractory depression.
Patients diagnosed with depression associated with both unipolar and bipolar mood disorders are believed to be able to completely recover and achieve full remission (Kraepelin, 1913; Weitbrecht, 1973) . However, in previous studies, long-term observation until full remission has not been attained. By the 1995 evaluation in the present study, patients with antidepressant-refractory depression had suffered from chronic depression for an average of 5 years, for unipolar depression, and 3.4 years, for bipolar depression.
Nevertheless, during the long-term follow-up of the present study, we confirmed that 8 of 10 bipolar depressed patients and 9 of 16 unipolar depressed patients achieved full remission. While full remission of these depressed patients is likely in principle, as observed by Emil Kraepelin (1913) , it is clinically important to confirm in naturalistic settings that chronic antidepressant-refractory depression is not a subgroup that is unable to achieve full remission.
During the follow-up period, recurrence occurred in only 2 of 10 remitted unipolar depressed patients, and these patients were remitted thereafter again. In bipolar depressed patients, 5 of 10 patients experienced recurrence of depression and 7 of 10 patients experienced hypomanic/manic episodes. Accordingly, as also shown in the 1995 study, bipolar antidepressant-refractory patients had more episodes than unipolar antidepressant-refractory depressed patients. The prevention of such mood episodes by mood stabilizers might be important for these bipolar antidepressant-refractory depressed patients, although they continue to have chronic episodes of depression for years.
However, as half of the bipolar patients had been diagnosed with unipolar depression in 1995 because of a lack of previous manic or hypomanic episodes, they could not receive mood stabilizers until the final diagnosis was made. Therefore, the diagnosis of bipolar depression before the first manic/hypomanic episode is an important issue.
For effective treatment of refractory depression, several limitations of our study must be considered: the choice of augmentation therapies used for our patients was not controlled, and their efficacies were evaluated based on the CGI scale. Nevertheless, we can suggest that lithium, L-thyroxine, and dopamine receptor agonists, in combination with antidepressants, are effective treatments for patients with either unipolar or bipolar antidepressant-refractory depression. Meta-analyses based on placebo-controlled double-blind studies have confirmed the efficacy of lithium, but not triiodotyronine, for refractory depression (Aronson et al., 1996; Bauer and Döpfmer, 1999) . However, a systematic review indicated that even the evidence for lithium augmentation is very weak (Stimpson et al., 2002) . Despite limited evidence, clinicians must pursue effective pharmacological therapies for antidepressant-refractory depression for the benefit of these patients. L-thyroxine and dopamine receptor agonists have not been investigated by randomized controlled trials for antidepressant-refractory depression, however, their efficacies were reported in open-labeled trials (Inoue et al., 1996b; Bauer et al., 1998) . The present study showed that the addition of dopamine receptor agonists was effective in 9 of 13 patients with full remission as the final evaluation, the addition of lithium and a dopamine receptor agonist was effective in 1 patient, and the addition of lithium and L-thyroxine was effective in 2 patients. Accordingly, these augmentation therapies were considered helpful for these remitted patients at the final evaluations in long-term naturalistic observations without any serious side effects.
Interestingly, 1 of 4 lithium responders began the follow-up with a bipolar disorder; however, these responders consisted of 3 bipolar and 1 unipolar patients by the conclusion of the study. Previous studies have primarily examined the effect of lithium augmentation among unipolar depressed patients. However, with only a small number of bipolar depressed patients, a meta-analysis could not draw conclusion as to whether bipolar patients are more or less likely responders compared with unipolar depressed patients (Bauer and Döpfmer, 1999) . Future studies should compare the response rate to lithium augmentation among unipolar and bipolar depressed patients who have been diagnosed based on long-term observation.
